Fraud Allegations Hit Outset Medical, Inc. – Investors Alerted

Allegations Unveiled

LOS ANGELES, Sept. 6, 2024 — The Law Offices of Frank R. Cruz announces that investors with substantial losses have the opportunity to lead the securities fraud class action lawsuit against Outset Medical, Inc. (“Outset Medical” or the “Company”) OM.

Class Period: August 1, 2022 – August 7, 2024
Lead Plaintiff Deadline: October 28, 2024

The complaint alleges that, throughout the Class Period, Defendants failed to disclose to investors various critical pieces of information about the Tablo products. These include marketing the products for continuous renal replacement therapy, which was not approved by the FDA, the likelihood of submitting an additional 510(k) application, and the risk of halting sales of the Tablo products until FDA approval among other financial intricacies that are part of the basis for the class action lawsuit.

Investor Rights

Investors who suffered losses during the specified period are advised to consider their rights and potential participation in the lawsuit. The Company’s revenue growth prospects and operational integrity were called into question by the alleged misleading statements.

For further details and information on the class-action lawsuit, interested parties can contact The Law Offices of Frank R. Cruz. There is no immediate requirement to take action to become part of the class action, but one can choose to engage with legal counsel for consultation.

Legal Implications

This press release may be deemed Attorney Advertising in some jurisdictions per applicable law and ethical standards.